Abstract
Purpose
Cytoreductive therapy is beneficial in patients with essential thrombocythemia at high risk of thrombosis. However its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET aged 40-59 and without high-risk factors or extreme thrombocytosis.
Methods
Patients were aged 40-59 years and lacked a history of ischemia, thrombosis, embolism, hemorrhage, extreme thrombocytosis (≥1500x109/L), or hypertension or diabetes requiring therapy. 382 patients were randomized 1:1 to hydroxycarbamide plus aspirin or aspirin alone. The composite primary endpoint was time to arterial or venous thrombosis, serious hemorrhage or death from vascular causes. Secondary endpoints were time to first arterial or venous thrombosis, first serious hemorrhage, death, incidence of transformation and patient-reported quality of life.
Results
After a median follow-up of 73 months and a total follow-up of 2373 patient years there was no significant difference between the arms in the likelihood of patients reaching the primary endpoint (hazard ratio 0.98, 95% CI 0.42-2.25, P=1.0). The incidence of significant vascular events was low, at 0.93 per 100 patient-years (95% CI 0.61-1.41). There were also no differences in overall survival, in the composite endpoint of transformation to myelofibrosis, acute myeloid leukaemia or myelodysplasia, in adverse events or in patient-reported quality of life.
Conclusions
In ET patients aged 40-59 and lacking high-risk factors for thrombosis or extreme thrombocytosis, pre-emptive addition of hydroxycarbamide to aspirin did not reduce vascular events, myelofibrotic or leukemic transformation. Patients aged 40-59 without other clinical indications for treatment (such as previous thrombosis or haemorrhage), who have a platelet count less than 1500x109/L, should not receive cytoreductive therapy.
Cytoreductive therapy is beneficial in patients with essential thrombocythemia at high risk of thrombosis. However its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET aged 40-59 and without high-risk factors or extreme thrombocytosis.
Methods
Patients were aged 40-59 years and lacked a history of ischemia, thrombosis, embolism, hemorrhage, extreme thrombocytosis (≥1500x109/L), or hypertension or diabetes requiring therapy. 382 patients were randomized 1:1 to hydroxycarbamide plus aspirin or aspirin alone. The composite primary endpoint was time to arterial or venous thrombosis, serious hemorrhage or death from vascular causes. Secondary endpoints were time to first arterial or venous thrombosis, first serious hemorrhage, death, incidence of transformation and patient-reported quality of life.
Results
After a median follow-up of 73 months and a total follow-up of 2373 patient years there was no significant difference between the arms in the likelihood of patients reaching the primary endpoint (hazard ratio 0.98, 95% CI 0.42-2.25, P=1.0). The incidence of significant vascular events was low, at 0.93 per 100 patient-years (95% CI 0.61-1.41). There were also no differences in overall survival, in the composite endpoint of transformation to myelofibrosis, acute myeloid leukaemia or myelodysplasia, in adverse events or in patient-reported quality of life.
Conclusions
In ET patients aged 40-59 and lacking high-risk factors for thrombosis or extreme thrombocytosis, pre-emptive addition of hydroxycarbamide to aspirin did not reduce vascular events, myelofibrotic or leukemic transformation. Patients aged 40-59 without other clinical indications for treatment (such as previous thrombosis or haemorrhage), who have a platelet count less than 1500x109/L, should not receive cytoreductive therapy.
| Original language | English |
|---|---|
| Number of pages | 11 |
| Journal | Journal of Clinical Oncology |
| Early online date | 28 Aug 2018 |
| DOIs | |
| Publication status | Early online date - 28 Aug 2018 |
Access to Document
- Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
© 2018 The Authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
- Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
Copyright 2018 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Fingerprint
Dive into the research topics of 'Hydroxycarbamide plus Aspirin vs Aspirin Alone in Patients with Essential Thrombocythaemia Aged 40-59 Years Without High-Risk Features'. Together they form a unique fingerprint.Profiles
-
Mary Frances McMullin
- School of Medicine, Dentistry and Biomedical Sciences - Clinical Professor
Person: Academic